Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 35

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 35
---
37,000 | ​ | ​ |
| Tax Fees                     | ​ | ​ | ​                                  | ​ |       — | ​ | ​ | ​ | ​                                  | ​ |       — | ​ | ​ |
| All Other Fees               | ​ | ​ | ​                                  | ​ |  10,000 | ​ | ​ | ​ | ​                                  | ​ |  10,000 | ​ | ​ |
| Total                        | ​ | ​ | ​                                  | $ | 600,000 | ​ | ​ | ​ | ​                                  | $ | 740,000 | ​ | ​ |

Representatives of Ernst & Young attended the majority of the meetings of the Audit Committee occurring during the years ended December 31, 2024 and 2023. Pre-Approval Policies and Procedures The Audit Committee approves in advance the engagement and fees of the independent registered public accounting firm for all audit services and non-audit services, based upon independence, qualifications and, if applicable, performance. The Audit Committee may form and delegate to subcommittees of one or more members of the Audit Committee the authority to grant pre-approvals for audit and permitted non-audit services, up to specific amounts. All audit services provided by Ernst & Young for the periods presented were pre-approved by the Audit Committee.

22

Ability to Continue as a Going Concern The report of Ernst & Young on the consolidated financial statements of Armata Pharmaceuticals, Inc. for the fiscal year ended December 31, 2024, included in Armata’s Annual Report on Form 10-K, filed on March 21, 2025, stated that Armata has suffered recurring losses and negative cash flows from operations, which raised substantial doubt about Armata’s ability to continue as a going concern. Other than the foregoing, Ernst & Young’s report on our financial statements for the past two years contained no adverse opinion or disclaimer of opinion and was not qualified as to audit scope or accounting principles. The Board of Directors Recommends
a Vote “For” Proposal 3 . 23

EXECUTIVE OFFICERS The following table sets forth information regarding our executive officers as of the record date.

| Name                  | ​ | ​ | Age | ​ | ​ | Position(s)                                                    | ​ |
| Deborah L. Birx, M.D. | ​ | ​ |  69 | ​ | ​ | Chief Executive Officer and Director                           | ​ |
| David D. House        | ​ | ​ |  41 | ​ | ​ | Senior Vice President